Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00030485
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.

Key Dates

First listed
Jan 27, 2003
Start date
Jan 31, 2002
Status verified
Jan 2011
Primary completion
Apr 30, 2007
Completion
Apr 30, 2007

Study Design

Primary purpose
TREATMENT

Related Studies